GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Cannabis Bioscience International Holdings Inc (OTCPK:CBIH) » Definitions » Cash Conversion Cycle

Cannabis Bioscience International Holdings (Cannabis Bioscience International Holdings) Cash Conversion Cycle : -1,601.98 (As of Nov. 2023)


View and export this data going back to 2008. Start your Free Trial

What is Cannabis Bioscience International Holdings Cash Conversion Cycle?

Cash Conversion Cycle is one of several measures of management effectiveness. It equals Days Sales Outstanding + Days Inventory - Days Payable.

Cannabis Bioscience International Holdings's Days Sales Outstanding for the six months ended in Nov. 2023 was 25.31.
Cannabis Bioscience International Holdings's Days Inventory for the six months ended in Nov. 2023 was 0.
Cannabis Bioscience International Holdings's Days Payable for the six months ended in Nov. 2023 was 1627.29.
Therefore, Cannabis Bioscience International Holdings's Cash Conversion Cycle (CCC) for the six months ended in Nov. 2023 was -1,601.98.


Cannabis Bioscience International Holdings Cash Conversion Cycle Historical Data

The historical data trend for Cannabis Bioscience International Holdings's Cash Conversion Cycle can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cannabis Bioscience International Holdings Cash Conversion Cycle Chart

Cannabis Bioscience International Holdings Annual Data
Trend Dec06 Dec07 May09 May10 May11
Cash Conversion Cycle
-1,013.89 - 115.88 124.89 99.77

Cannabis Bioscience International Holdings Semi-Annual Data
Dec06 Jun07 Dec07 Jun08 May09 Nov09 May10 Nov10 May11 Nov11 Nov22 Nov23
Cash Conversion Cycle Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only 155.09 127.38 84.73 -23,334.62 -1,601.98

Competitive Comparison of Cannabis Bioscience International Holdings's Cash Conversion Cycle

For the Drug Manufacturers - Specialty & Generic subindustry, Cannabis Bioscience International Holdings's Cash Conversion Cycle, along with its competitors' market caps and Cash Conversion Cycle data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Cannabis Bioscience International Holdings's Cash Conversion Cycle Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Cannabis Bioscience International Holdings's Cash Conversion Cycle distribution charts can be found below:

* The bar in red indicates where Cannabis Bioscience International Holdings's Cash Conversion Cycle falls into.



Cannabis Bioscience International Holdings Cash Conversion Cycle Calculation

Cash Conversion Cycle (CCC) measures how fast a company can convert cash on hand into even more cash on hand. This metric looks at the amount of time needed to sell inventory, the amount of time needed to collect receivables and the length of time the company is afforded to pay its bills without incurring penalties.

Cash Conversion Cycle is one of several measures of management effectiveness.

Cannabis Bioscience International Holdings's Cash Conversion Cycle for the fiscal year that ended in May. 2011 is calculated as

Cash Conversion Cycle=Days Sales Outstanding +Days Inventory-Days Payable
=182.52+2.99-85.74
=99.77

Cannabis Bioscience International Holdings's Cash Conversion Cycle for the quarter that ended in Nov. 2023 is calculated as:

Cash Conversion Cycle=Days Sales Outstanding+Days Inventory-Days Payable
=25.31+0-1627.29
=-1,601.98

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Cannabis Bioscience International Holdings  (OTCPK:CBIH) Cash Conversion Cycle Explanation

Generally, the lower this number is, the better for the company. Although it should be combined with other metrics (such as ROE % and ROA %), it can be especially useful for comparing close competitors, because the company with the lowest CCC is often the one with better management.


Be Aware

CCC is most effective with retail-type companies, which have inventories that are sold to customers. Consulting businesses, software companies and insurance companies are all examples of companies for whom this metric is meaningless.

The CCC is one of several tools that can help you evaluate management, especially if it is calculated for several consecutive time periods and for several competitors. Decreasing or steady CCCs are good, while rising ones should motivate you to dig a bit deeper.


Cannabis Bioscience International Holdings Cash Conversion Cycle Related Terms

Thank you for viewing the detailed overview of Cannabis Bioscience International Holdings's Cash Conversion Cycle provided by GuruFocus.com. Please click on the following links to see related term pages.


Cannabis Bioscience International Holdings (Cannabis Bioscience International Holdings) Business Description

Traded in Other Exchanges
N/A
Address
6201 Bonhomme Road, Suite 466S, Houston, TX, USA, 77036
Cannabis Bioscience International Holdings Inc is engaged in providing educational systems relating to cannabis and services in therapeutic areas. of clinical trials and services relating to sleep disorders through its sleep center in Houston, Texas. The Company generates revenue from multiple streams, namely, clinical trials, consulting fees, video courses, seminars, royalties, and merchandise sales. The company generates the majority of its revenue from clinical trials.